JAMA dermatologyPub Date : 2025-02-01DOI: 10.1001/jamadermatol.2024.5542
Seneca D Hutson, Mary E Lohman, Emma F Johnson
{"title":"Smooth, Firm, Skin-Colored Papules on the Nasal Dorsum.","authors":"Seneca D Hutson, Mary E Lohman, Emma F Johnson","doi":"10.1001/jamadermatol.2024.5542","DOIUrl":"10.1001/jamadermatol.2024.5542","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"214-215"},"PeriodicalIF":11.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JAMA dermatologyPub Date : 2025-02-01DOI: 10.1001/jamadermatol.2024.5044
Dorian Kern, Brjánn Ljótsson, Louise Lönndahl, Erik Hedman-Lagerlöf, Olof Molander, Björn Liliequist, Maria Bradley, Nils Lindefors, Martin Kraepelien
{"title":"Self-Guided vs Clinician-Guided Online Cognitive Behavioral Therapy for Atopic Dermatitis: A Randomized Clinical Trial.","authors":"Dorian Kern, Brjánn Ljótsson, Louise Lönndahl, Erik Hedman-Lagerlöf, Olof Molander, Björn Liliequist, Maria Bradley, Nils Lindefors, Martin Kraepelien","doi":"10.1001/jamadermatol.2024.5044","DOIUrl":"10.1001/jamadermatol.2024.5044","url":null,"abstract":"<p><strong>Importance: </strong>Clinician-guided online self-help based on cognitive behavioral therapy (CBT) has been shown to be effective at decreasing symptom severity for people with atopic dermatitis (AD). A brief online self-guided CBT intervention could be more cost-effective and allow for easy implementation and broader outreach compared with more comprehensive clinician-guided interventions.</p><p><strong>Objective: </strong>To investigate whether a brief online self-guided CBT intervention is noninferior to a comprehensive online clinician-guided CBT treatment.</p><p><strong>Design, setting, and participants: </strong>This single-blind randomized clinical noninferiority trial was conducted at Karolinska Institutet, Stockholm, Sweden. Adult individuals with AD were enrolled from November 2022 to April 2023. The last postintervention data were collected in December 2023.</p><p><strong>Interventions: </strong>Participants randomized to the self-guided group had access to a self-guided online CBT intervention for 12 weeks without clinician support. Participants randomized to the clinician-guided group received online CBT for 12 weeks.</p><p><strong>Main outcomes and measures: </strong>The primary outcome was change in score from baseline to postintervention to 12-week follow-up on the self-reported Patient-Oriented Eczema Measure (POEM). The predefined noninferiority margin was 3 points on POEM.</p><p><strong>Results: </strong>Of 168 randomized participants, 142 (84.5%) were female, and the mean (SD) age was 39 (10.5) years. A total of 86 participants were randomized to the self-guided group and 82 were randomized to the clinician-guided group. A total of 151 (90.0%) completed the main outcome postintervention assessment. Postintervention, the clinician-guided group had improved 4.20 points (95% CI, 1.94-6.05) on POEM and the self-guided group improved 4.60 points (95% CI, 2.57-6.64), corresponding to an estimated mean difference in change of 0.36 points (1-sided 97.5% CI, -∞ to 1.75), which was below the noninferiority margin of 3 points. No serious adverse events were reported. In the clinician-guided group, clinicians spent a mean (SD) of 36.0 (33.3) minutes (95% CI, 29.2-41.7) on treatment guidance and 14.0 (6.0) minutes (95% CI, 12.9-15.6) on assessments compared to 15.8 (6.4) minutes on assessments in the self-guided group.</p><p><strong>Conclusions and relevance: </strong>In this randomized clinical noninferiority trial, a brief self-guided CBT intervention was noninferior to clinician-guided CBT. Given the limited clinical resources required to deliver self-guided CBT, this treatment might be a promising means to disseminate evidence-based psychological treatment for patients with AD.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT05517850.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"183-190"},"PeriodicalIF":11.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11840653/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JAMA dermatologyPub Date : 2025-02-01DOI: 10.1001/jamadermatol.2024.4900
Serigne N Lo, Gabrielle J Williams, Anne E Cust, David W Ollila, Alexander H R Varey, Sydney Ch'ng, Richard A Scolyer, John F Thompson
{"title":"Risk of Death Due to Melanoma and Other Causes in Patients With Thin Cutaneous Melanomas.","authors":"Serigne N Lo, Gabrielle J Williams, Anne E Cust, David W Ollila, Alexander H R Varey, Sydney Ch'ng, Richard A Scolyer, John F Thompson","doi":"10.1001/jamadermatol.2024.4900","DOIUrl":"10.1001/jamadermatol.2024.4900","url":null,"abstract":"<p><strong>Importance: </strong>Most patients who present with primary cutaneous melanomas have thin tumors (≤1.0 mm in Breslow thickness, ie, pT1a and pT1b). Although their prognosis is generally considered to be excellent, there is limited precise information on the association of risk of death with specific Breslow measurements in thin lesions.</p><p><strong>Objective: </strong>To assess the relative effect of a 0.8-mm Breslow thickness threshold with respect to the incidence of both melanoma-related and nonmelanoma-related death.</p><p><strong>Design, setting, and participants: </strong>Registry data for all Australians diagnosed with thin invasive primary melanomas between 1982 and 2014 were analyzed. Data were extracted from all 8 Australian state and territory population-based cancer registries. Dates and causes of death were obtained from the Australian National Death Index. Adults diagnosed with a first invasive primary melanoma of 1.0 mm or smaller in thickness were included.</p><p><strong>Exposure: </strong>First invasive primary melanoma between 1982 and 2014.</p><p><strong>Main outcomes and measures: </strong>The primary outcomes were melanoma-related deaths and nonmelanoma-related deaths. Competing-risk regression analyses and cause-specific analyses were performed to investigate the relationships between Breslow thickness subcategory (<0.8 mm versus ≥0.8 mm by 0.1-mm increments) and the primary outcomes.</p><p><strong>Results: </strong>Overall, a cohort of 144 447 participants was included. The median (range) age was 56 (18-101) years and 78 014 (54.0%) were men. Median (IQR) follow-up was 15.0 (9.5-23.3) years. Crude incidence rates of melanoma-related death 20 years after diagnosis were 6.3% (95% CI, 6.1%-6.5%) for the whole cohort, 6.0% (95% CI, 5.7%-6.2%) for tumors smaller than 0.8 mm, and 12.0% (95% CI, 11.4%-12.6%) for tumors 0.8 to 1.0 mm. The corresponding 20-year melanoma-specific survival rates were 91.9% (95% CI, 91.6%-92.1%), 94.2% (95% CI, 94.0%-94.4%), and 87.8% (95% CI, 87.3%-88.3%), respectively. On multivariable analysis, tumor thickness of 0.8 to 1.0 mm was significantly associated with both a greater absolute risk of melanoma-related death (subdistribution hazard ratio, 2.92; 95% CI, 2.74-3.12) and a greater rate of melanoma-related death (hazard ratio, 2.98; 95% CI, 2.79-3.18) than thinner tumors (<0.8 mm). Risk of death from nonmelanoma-related causes was not associated with Breslow thickness.</p><p><strong>Conclusions and relevance: </strong>In this study, the risk of melanoma-related death increased significantly for patients with primary tumors of 0.8 to 1.0 mm in thickness. The risk of death from nonmelanoma-ralated causes was similar across Breslow thicknesses of 0.1 to 1.0 mm. This analysis suggests that a 0.8-mm threshold for guiding the care of patients with thin primary melanomas.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"167-174"},"PeriodicalIF":11.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11840651/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142807241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JAMA dermatologyPub Date : 2025-02-01DOI: 10.1001/jamadermatol.2024.5141
Michelle Sikora, Chinemelum Obijiofor, Angelo Osofsky, Lynn Liu, Soutrik Mandal, Kristen I Lo Sicco, Avrom S Caplan
{"title":"Sarcoidosis-Specific Cutaneous Lesion Distribution in Clinical Assessment for Cardiac Sarcoidosis.","authors":"Michelle Sikora, Chinemelum Obijiofor, Angelo Osofsky, Lynn Liu, Soutrik Mandal, Kristen I Lo Sicco, Avrom S Caplan","doi":"10.1001/jamadermatol.2024.5141","DOIUrl":"10.1001/jamadermatol.2024.5141","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"218-221"},"PeriodicalIF":11.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11840637/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JAMA dermatologyPub Date : 2025-02-01DOI: 10.1001/jamadermatol.2024.5359
Ervin Epstein, Gerald S Lazarus, Luis A Diaz
{"title":"Lowell A. Goldsmith, MD, MPH, 1938-2024-A Personal Remembrance From 3 Friends.","authors":"Ervin Epstein, Gerald S Lazarus, Luis A Diaz","doi":"10.1001/jamadermatol.2024.5359","DOIUrl":"https://doi.org/10.1001/jamadermatol.2024.5359","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":"161 2","pages":"123-124"},"PeriodicalIF":11.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143449098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JAMA dermatologyPub Date : 2025-02-01DOI: 10.1001/jamadermatol.2024.5567
Anna Brinks, Carli Needle, Kristen Lo Sicco
{"title":"Methotrexate and Interstitial Lung Disease.","authors":"Anna Brinks, Carli Needle, Kristen Lo Sicco","doi":"10.1001/jamadermatol.2024.5567","DOIUrl":"10.1001/jamadermatol.2024.5567","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"231-232"},"PeriodicalIF":11.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JAMA dermatologyPub Date : 2025-02-01DOI: 10.1001/jamadermatol.2024.4914
Ian A Myles, Jeffrey B Kopp
{"title":"Salt and Atopic Dermatitis.","authors":"Ian A Myles, Jeffrey B Kopp","doi":"10.1001/jamadermatol.2024.4914","DOIUrl":"10.1001/jamadermatol.2024.4914","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"228-229"},"PeriodicalIF":11.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JAMA dermatologyPub Date : 2025-02-01DOI: 10.1001/jamadermatol.2024.4911
Brenda M Chiang, Morgan Ye, Katrina Abuabara
{"title":"Salt and Atopic Dermatitis-Reply.","authors":"Brenda M Chiang, Morgan Ye, Katrina Abuabara","doi":"10.1001/jamadermatol.2024.4911","DOIUrl":"10.1001/jamadermatol.2024.4911","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"229-230"},"PeriodicalIF":11.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}